Klara Dickinson Net Worth

Klara Dickinson biography

Klara Dickinson serves as Chief Regulatory and Compliance Officer of the Company. Prior to that she was our Senior Vice President, Regulatory Affairs and Compliance since June 2017. Previously, she served as Senior Vice President, Chief Regulatory Officer at Anthera Pharmaceuticals, Inc., a biopharmaceutical company, from 2014 to 2017, where she was responsible for the general supervision of the company’s regulatory affairs. From 2007 to 2014, she was Senior Vice President of Regulatory Affairs and Compliance at Hyperion Therapeutics, Inc. Ms. Dickinson also spent three years at CoTherix, Inc. as Vice President, Regulatory Affairs and Healthcare Compliance Officer, and held various positions at biopharmaceutical companies such as Scios, Inc. and DEY Laboratories (a subsidiary of Mylan, Inc.). Ms. Dickinson holds a B.S. in Biology from the College of Great Falls in Montana and is certified by the Regulatory Affairs Certification Board.

What is the salary of Klara Dickinson?

As the Chief Regulatory and Compliance Officer of Cymabay Therapeutics Inc, the total compensation of Klara Dickinson at Cymabay Therapeutics Inc is $1,237,250. There are 2 executives at Cymabay Therapeutics Inc getting paid more, with Sujal Shah having the highest compensation of $2,556,470.

How old is Klara Dickinson?

Klara Dickinson is 53, she's been the Chief Regulatory and Compliance Officer of Cymabay Therapeutics Inc since 2019. There are 8 older and 7 younger executives at Cymabay Therapeutics Inc. The oldest executive at Cymabay Therapeutics Inc is Robert Wills, 66, who is the Independent Chairman of the Board.

What's Klara Dickinson's mailing address?

Klara's mailing address filed with the SEC is C/O CYMABAY THERAPEUTICS, INC., 7601 DUMBARTON CIRCLE, FREMONT, CA, 94555.

Insiders trading at Cymabay Therapeutics Inc

Over the last 10 years, insiders at Cymabay Therapeutics Inc have traded over $17,635,452 worth of Cymabay Therapeutics Inc stock and bought 2,170,647 units worth $6,725,086 . The most active insiders traders include Capital Advisors Llc Aghaza..., Kurt Von Emster, eCarl Goldfischer. On average, Cymabay Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,796,241. The most recent stock trade was executed by Sujal Shah on 13 March 2024, trading 139,119 units of CBAY stock currently worth $656,642.

What does Cymabay Therapeutics Inc do?

cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.

Cymabay Therapeutics Inc executives and stock owners

Cymabay Therapeutics Inc executives and other stock owners filed with the SEC include:

• Sujal Shah,
  President, Chief Executive Officer, Director
• Charles McWherter,
  Senior Vice President, Chief Scientific Officer
• Klara Dickinson,
  Chief Regulatory and Compliance Officer
• Daniel Menold,
  Vice President - Finance
• Sujal A. Shah,
  Pres, CEO & Director
• Dr. Charles A. McWherter Ph.D.,
  Chief Scientific Officer
• Paul T. Quinlan,
  Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Robert Wills,
  Independent Chairman of the Board
• Kurt von Emster,
  Independent Director
• Paul Truex,
  Independent Director
• Caroline Loewy,
  Independent Director
• Dr. Dennis D. Kim M.B.A., M.D., MBA,
  Chief Medical Officer
• Becki Filice,
  Sr. VP of Portfolio & Product Leadership
• Klara A. Dickinson-Eason,
  Chief Regulatory & Quality Assurance Officer
• Dr. Robert L. Martin,
  Sr. VP of Manufacturing & Nonclinical Devel.
• Patrick J. O'Mara,
  Sr. VP of Bus. Devel.
• Ken Boehm,
  Sr. VP of HR
• Daniel Menold,
  VP of Fin.
• Evan A. Stein,
  Director
• Robert F. Booth,
  Director
• Carl Goldfischer,
  Director
• Pol F Boudes,
  Chief Medical Officer
• Robert J. Weiland,
  Director
• Kirk Rosemark,
  V.P. Regulatory & Quality
• Wart Harold Van,
  President and CEO
• Emster Kurt Von,
  Director
• Thomas G Wiggans,
  
• Paul T Quinlan,
  General Counsel
• Eric Lefebvre,
  
• Harish Shantharam,
  Chief Financial Officer
• Lewis J Stuart,
  Chief Commercial Officer
• Patrick J. O Mara,
  VP, Business Development
• Robert L. Martin,
  Sr. Vice President
• Capital Advisors Llc Aghaza...,
  
• Edward Penhoet,
  Director
• Louis G Lange,
  Director
• Hari Kumar,
  Director
• Janet Dorling,
  
• Dennis D Kim,
  Chief Medical Officer